Mythic Therapeutics
Leave less to chance: sending ADCs to their targets with FateControl™
Key Highlights
- Helping ADCs Find Their Fate: Mythic manipulates the trafficking of antibody drug conjugates in cells with FateControl to increase uptake in the desired tissue while avoiding payload release in undesired tissues – potentially increasing therapeutic potency and improving tolerability.
- Well-Known Target, Common in NSCLC? It’s KisMET: Therapeutic pipeline is led by KisMET-01 clinical study of MYTX-011, a cMET targeted ADC, for treatment of NSCLC where 70% of tumors have cMET over-expression. Notably, Mythic is pursuing a left behind patient population – those with low-to-moderate cMET expression
- Key Events in 2024: Progress of KisMET-01 and presentation of preliminary data